Pricing
  1. US-listed companies
  2. KYNTRA BIO, INC.
  3. Financials
  4. Accounts receivable, net

KYNTRA BIO, INC.【KYNB】

Market cap
$28.19M
P/E ratio
SummaryFinancials
Period EndAccounts receivable, net (Million USD)YoY (%)
Dec 31, 20240-96.17%
Dec 31, 202313-22.98%
Dec 31, 202216-6.33%
Dec 31, 202117-58.45%
Dec 31, 202042+47.19%
Dec 31, 201928-55.32%
Dec 31, 201864+653.48%
Dec 31, 20178-19.10%
Dec 31, 201610-32.18%
Dec 31, 201515

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)